The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF).
Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient.
Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
Prior exposure to KAT6A/B inhibitors/degraders.
A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.
Known central nervous system involvement by leukemia
Use of antileukemic therapies without sufficient washout period